121 patents
Utility
Methods of Treating Neuroepithelial Tumors Using Selective Glucocorticoid Receptor Modulators
11 Jan 24
Applicant discloses methods for treating a glucocorticoid receptor positive (GR+) neuroepithelial tumor in a subject, comprising administering a selective glucocorticoid receptor modulator (SGRM) in an amount effective to reduce the tumor load in a subject.
Andreas G. Moraitis
Filed: 15 Sep 23
Utility
Concomitant Administration of Glucocorticoid Receptor Modulators and CYP3A Inhibitors
28 Dec 23
Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor modulator (GRM) and steroidogenesis inhibitors, and by concomitant administration of a GRM and CYP3A inhibitors.
Joseph K. Belanoff
Filed: 1 Sep 23
Utility
Methods of Preparing Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulators
28 Dec 23
The present invention provides methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators, and compositions having low impurity levels.
Hazel Joan Hunt, Gary Patrick Reid, Jeffrey Mark Dener, Adam Daisuke Gammack Yamagata, Gareth C. Sheppard
Filed: 27 Jun 23
Utility
Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
28 Nov 23
The present invention provides methods of preparing 2-amino-6-((1r,4r)-4-phenylcyclohexyl)-5-(3-(trifluoromethyl)benzyl)pyrimidin-4(3H)-one, and 2-amino-6-((1r,4r)-4-phenylcyclohexyl)-5-(3-(trifluoromethyl)benzyl)pyrimidin-4(3H)-one monohydrate, as well as new intermediate compounds.
Jeffrey Mark Dener, Hazel Joan Hunt, Nicholas David Tyrrell
Filed: 20 Dec 21
Utility
Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient
23 Nov 23
Methods and uses are disclosed for treating a subject suffering from a disorder selected from a liver disorder, Cushing's syndrome, or Cushing's Disease, cancer, an infection, an inflammatory condition, a cardiovascular, endocrine, or kidney disease, and combinations thereof, or other disorder for which they may be administered a drug which may cause liver toxicity, without adverse effects on the liver.
Andreas Moraitis
Filed: 19 May 23
Utility
Glucocorticoid Receptor Modulators to Treat Cervical Cancer
9 Nov 23
Methods for treating a subject having a cancerous tumor are disclosed.
Hazel Hunt
Filed: 18 Apr 23
Utility
Treatment Of, and Differential Diagnosis Between, Acth-dependent Cushing's Syndrome and Acth-independent Cushing's Syndrome
9 Nov 23
Methods for treating and differential diagnosis between ACTH-Dependent and ACTH-Independent Cushing's syndrome are disclosed, in which a glucocorticoid receptor antagonist (GRA) is administered to a Cushing's syndrome patient with a basal ACTH level less than about 25 pg/mL.
Andreas G. Moraitis, Joseph Belanoff
Filed: 18 Dec 20
Utility
Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator
2 Nov 23
Andreas Moraitis
Filed: 9 May 23
Utility
Methods of Stimulating an Anti-tumor Response Using a Selective Glucocorticoid Receptor Modulator
2 Nov 23
Methods of improving immune function in a cancer patient having a solid tumor are disclosed.
Andrew E. Greenstein, Andreas Grauer, Stacie Peacock Shepherd
Filed: 10 Feb 21
Utility
Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
24 Oct 23
Applicant discloses methods for treating a glucocorticoid receptor positive (GR+) neuroepithelial tumor in a subject, comprising administering a selective glucocorticoid receptor modulator (SGRM) in an amount effective to reduce the tumor load in subject.
Andreas G. Moraitis
Filed: 19 Nov 21
Utility
Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulators
19 Oct 23
The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators, including their use for treating amyotrophic lateral sclerosis (ALS).
Hazel Hunt, Tony Johnson, Nicholas Ray, Iain Walters
Filed: 15 Mar 23
Utility
Quaternary indazole glucocorticoid receptor antagonists
17 Oct 23
The present disclosure provides compounds of Formula I or II.
Hazel Hunt, Lorna Duffy, Ian Strutt, Morgan Jouanneau, Thomas Hornsby, Mark Mills, Andrew William Phillips, Jon-Paul Ward
Filed: 21 Jun 21
Utility
Method for Differentially Diagnosing Acth-dependent Cushing's Syndrome
12 Oct 23
Applicant discloses herein methods for differentially diagnosing adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome in a patient where the differential diagnosis is between ectopic ACTH syndrome and Cushing Disease.
Andreas G. Moraitis
Filed: 9 Jun 23
Utility
Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
19 Sep 23
The present invention provides crystalline forms of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, and methods of making and using the same.
Hazel Joan Hunt, Lorraine Donaghy, Keith Lorimer, Nathan Jay Dixon, Jeffrey Mark Dener
Filed: 5 Dec 22
Utility
Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer
14 Sep 23
Hazel Hunt, Thaddeus S. Block
Filed: 22 Mar 23
Utility
Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
5 Sep 23
This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia.
Andreas Moraitis
Filed: 31 Jul 20
Utility
Bicyclic Indazole Glucocorticoid Receptor Antagonists
3 Aug 23
The present disclosure provides compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2.
Lorna Duffy, Thomas Hornsby, Morgan Jouanneau, Mark Mills, Andrew William Phillips, Andrew James Smith, Hazel Joan Hunt, Peter Hunt
Filed: 20 Dec 22
Utility
Fatty Liver Disease Treatment Using Glucocorticoid and Mineralocorticoid Receptor Antagonists
13 Jul 23
The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.
Joseph K. Belanoff, Hazel Hunt, Onno C. Meijer, José van den Heuvel
Filed: 26 Jan 23
Utility
Polymorphs of Pyrimidine Cyclohexyl Glucocorticoid Receptor Modulators
6 Jul 23
The present invention provides crystalline forms of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, and methods of making and using the same.
Hazel Joan Hunt, Lorraine Donaghy, Keith Lorimer, Nathan Jay Dixon, Jeffrey Mark Dener
Filed: 5 Dec 22
Utility
Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
27 Jun 23
Andreas Moraitis
Filed: 20 Dec 22